
{
  "Company Overview": {
    "Name": "Titan Biotech Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs & Formln",
    "Business Description": "Manufacturer and exporter of biological products used in pharmaceutical, nutraceutical, food & beverages, biotechnology & fermentation, cosmetic, veterinary & animal feed, agriculture industries, microbiology culture media & plant tissue culture media, etc.",
    "Market Position": "Information not explicitly available in provided HTML." 
  },
  "Financial Metrics": {
    "Market Cap": "₹ 624 Cr.",
    "Current Price": "₹ 755",
    "High/Low": "₹ 1,018 / ₹ 400",
    "P/E Ratio": 24.7,
    "Book Value": "₹ 175",
    "Dividend Yield": "0.26%",
    "ROCE": "25.1%",
    "ROE": "20.4%",
    "Face Value": "₹ 10.0",
    "Debt-to-Equity Ratio": "Information not explicitly available in provided HTML."
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [40.86, 36.43, 32.94, 35.00, 41.83, 30.33, 36.84, 34.75, 43.43, 45.98, 39.92, 43.11, 39.89],
      "Expenses": [30.39, 27.74, 25.52, 26.93, 31.35, 26.19, 30.00, 26.86, 34.71, 35.38, 32.85, 34.86, 32.13],
      "Operating Profit": [10.47, 8.69, 7.42, 8.07, 10.48, 4.14, 6.84, 7.89, 8.72, 10.60, 7.07, 8.25, 7.76],
      "OPM %": ["25.62%", "23.85%", "22.53%", "23.06%", "25.05%", "13.65%", "18.57%", "22.71%", "20.08%", "23.05%", "17.71%", "19.14%", "19.45%"],
      "Other Income": [0.26, 0.23, 0.39, 0.32, 0.86, 0.28, 0.49, 0.28, 0.55, 0.44, 0.48, 0.62, 0.32],
      "Interest": [0.36, 0.34, 0.20, 0.18, 0.17, 0.14, 0.26, 0.29, 0.28, 0.26, 0.34, 0.31, 0.27],
      "Depreciation": [0.62, 0.62, 0.71, 0.60, 0.64, 0.65, 0.71, 0.80, 0.86, 0.83, 0.84, 1.05, 1.10],
      "Profit before tax": [9.75, 7.96, 6.90, 7.61, 10.53, 3.63, 6.36, 7.08, 8.13, 9.95, 6.37, 7.51, 6.71],
      "Tax %": ["21.85%", "25.25%", "25.51%", "24.05%", "24.98%", "25.62%", "27.04%", "23.73%", "25.71%", "25.63%", "24.02%", "24.23%", "25.48%"],
      "Net Profit": [7.61, 5.94, 5.15, 7.50, 9.13, 3.26, 4.95, 6.16, 6.52, 7.17, 5.00, 6.40, 6.70],
      "EPS in Rs": [7.73, 6.33, 6.04, 9.08, 11.05, 3.94, 5.99, 7.45, 7.89, 8.68, 6.05, 7.74, 8.11]
    },
    "Annual Results": {
      "Sales": [40, 46, 53, 57, 65, 79, 142, 124, 144, 164, 169],
      "Expenses": [36, 42, 47, 50, 56, 66, 96, 92, 114, 130, 135],
      "Operating Profit": [4, 4, 5, 7, 9, 13, 46, 31, 30, 34, 34],
      "OPM %": ["10%", "9%", "10%", "12%", "14%", "17%", "32%", "25%", "21%", "21%", "20%"],
      "Other Income": [0, 1, 0, 0, 1, 1, 0, 1, 2, 2, 2],
      "Interest": [1, 1, 1, 2, 2, 2, 2, 1, 1, 1, 1],
      "Depreciation": [1, 1, 1, 1, 2, 2, 2, 2, 3, 3, 4],
      "Profit before tax": [2, 3, 3, 4, 6, 10, 43, 29, 28, 32, 31],
      "Tax %": ["33%", "34%", "35%", "35%", "30%", "25%", "26%", "25%", "25%", "25%", "25%"],
      "Net Profit": [2, 2, 2, 3, 4, 8, 32, 22, 25, 25, 25],
      "EPS in Rs": [2.11, 2.29, 2.82, 3.28, 4.26, 8.56, 36.71, 26.24, 30.06, 30.07, 30.58]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth": {
        "10 Years": "%",
        "5 Years": "20%",
        "3 Years": "5%",
        "TTM": "16%"
      },
      "Compounded Profit Growth": {
        "10 Years": "%",
        "5 Years": "47%",
        "3 Years": "-7%",
        "TTM": "21%"
      },
      "Stock Price CAGR": {
        "10 Years": "37%",
        "5 Years": "82%",
        "3 Years": "41%",
        "1 Year": "84%"
      }
    },
    "Liquidity Ratios": {
      "Information not explicitly available in provided HTML.": null
    },
    "Profitability Ratios": {
      "Return on Equity": {
        "10 Years": "%",
        "5 Years": "28%",
        "3 Years": "24%",
        "Last Year": "20%"
      },
      "ROCE %": ["12%", "12%", "13%", "15%", "20%", "58%", "32%", "27%", "25%", "%"]
    },
    "Valuation Ratios": {
      "Information not explicitly available in provided HTML.": null
    },
    "Other Ratios": {
      "Debtor Days": [58, 47, 44, 49, 52, 54, 46, 48, 53, 42],
      "Inventory Days": [134, 118, 155, 202, 236, 259, 177, 206, 179, 208],
      "Days Payable": [17, 18, 15, 13, 24, 38, 20, 25, 27, 15],
      "Cash Conversion Cycle": [175, 147, 184, 239, 264, 276, 203, 230, 205, 234],
      "Working Capital Days": [144, 117, 140, 153, 152, 153, 109, 138, 127, 128]
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Sun Pharma.Inds.", "CMP": 1808.85, "P/E": 38.73, "Mar Cap": 434003.71, "Div Yld": 0.75, "NP Qtr": 3037.33, "Qtr Profit Var": 27.86, "Sales Qtr": 13291.39, "Qtr Sales Var": 9.01, "ROCE": 17.32},
      {"Name": "Cipla", "CMP": 1472.05, "P/E": 25.81, "Mar Cap": 118884.82, "Div Yld": 0.88, "NP Qtr": 1305.01, "Qtr Profit Var": 15.18, "Sales Qtr": 7051.02, "Qtr Sales Var": 5.58, "ROCE": 22.80},
      {"Name": "Mankind Pharma", "CMP": 2805.20, "P/E": 56.07, "Mar Cap": 112393.74, "Div Yld": 0.00, "NP Qtr": 634.43, "Qtr Profit Var": 34.84, "Sales Qtr": 2529.74, "Qtr Sales Var": 11.91, "ROCE": 24.57},
      {"Name": "Dr Reddy's Labs", "CMP": 1343.65, "P/E": 21.00, "Mar Cap": 112115.62, "Div Yld": 0.60, "NP Qtr": 1341.90, "Qtr Profit Var": -15.28, "Sales Qtr": 8038.20, "Qtr Sales Var": 16.45, "ROCE": 26.53},
      {"Name": "Lupin", "CMP": 2150.70, "P/E": 37.36, "Mar Cap": 98114.41, "Div Yld": 0.37, "NP Qtr": 859.48, "Qtr Profit Var": 74.12, "Sales Qtr": 5672.73, "Qtr Sales Var": 12.59, "ROCE": 15.72},
      {"Name": "Zydus Lifesci.", "CMP": 973.50, "P/E": 22.90, "Mar Cap": 97956.88, "Div Yld": 0.31, "NP Qtr": 920.20, "Qtr Profit Var": 13.62, "Sales Qtr": 5237.00, "Qtr Sales Var": 19.87, "ROCE": 22.34},
      {"Name": "Aurobindo Pharma", "CMP": 1241.70, "P/E": 19.96, "Mar Cap": 72756.00, "Div Yld": 0.36, "NP Qtr": 816.95, "Qtr Profit Var": 8.65, "Sales Qtr": 7796.07, "Qtr Sales Var": 7.99, "ROCE": 14.10},
      {"Name": "Titan Biotech", "CMP": 754.90, "P/E": 24.69, "Mar Cap": 623.83, "Div Yld": 0.26, "NP Qtr": 6.70, "Qtr Profit Var": 2.76, "Sales Qtr": 39.89, "Qtr Sales Var": -8.15, "ROCE": 25.14}
    ],
    "Median": {
      "CMP": 512.7,
      "P/E": 33.34,
      "Mar Cap": 2869.55,
      "Div Yld": 0.05,
      "NP Qtr": 17.27,
      "Qtr Profit Var": 19.36,
      "Sales Qtr": 188.19,
      "Qtr Sales Var": 9.43,
      "ROCE": 14.1
    }
  },
  "Other Insights": {
    "Pros": [
      "Company has reduced debt.",
      "Company is almost debt free.",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 24.0%"
    ],
    "Cons": [
      "The pros and cons are machine generated.",
      "Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis."
    ],
    "Shareholding Pattern Notes": [
      "The classifications might have changed from Sep'2022 onwards.",
      "The new XBRL format added more details from Sep'22 onwards.",
      "Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.",
      "Click on the line-items to see the names of individual entities."
    ]
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Promoters": [55.88, 55.88, 55.88, 55.87, 55.87, 55.87, 55.87, 55.87, 55.87, 55.87, 55.87, 55.87],
      "DIIs": [0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.23, 0.00, 0.00],
      "Public": [44.12, 44.12, 44.12, 44.11, 44.11, 44.12, 44.13, 44.13, 44.12, 43.90, 44.12, 44.13]
    },
    "Yearly": {
      "Promoters": [48.00, 48.00, 49.49, 54.35, 55.88, 55.88, 55.87, 55.87, 55.87],
      "DIIs": [0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.23, 0.00],
      "Public": [52.00, 52.00, 50.51, 45.65, 44.12, 44.12, 44.12, 43.90, 44.13]
    }
  }
}
